BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Enoch DA, Santos R, Phillips CJ, Micallef C, Murphy ME, Aliyu SH, Massey D, Brown NM. Real-world use of fidaxomicin in a large UK tertiary hospital: how effective is it for treating recurrent disease? J Hosp Infect 2018;100:142-6. [PMID: 29746874 DOI: 10.1016/j.jhin.2018.05.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Lawler AJ, Lambert PA, Worthington T. A Revised Understanding of Clostridioides difficile Spore Germination. Trends in Microbiology 2020;28:744-52. [DOI: 10.1016/j.tim.2020.03.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
2 Bradley C, Burdett H, Holden K, Holden E, Garvey M. How do we define recurrence in Clostridium difficile infection? Journal of Hospital Infection 2019;102:171-3. [DOI: 10.1016/j.jhin.2018.07.026] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
3 Biggs M, Iqbal T, Holden E, Clewer V, Garvey M. Effect of using fidaxomicin on recurrent Clostridium difficile infection. Journal of Hospital Infection 2019;102:165-7. [DOI: 10.1016/j.jhin.2018.12.018] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
4 Escudero-Sánchez R, Valencia-Alijo A, Cuéllar Tovar S, Merino-de Lucas E, García Fernández S, Gutiérrez-Rojas Á, Ramos-Martínez A, Salavert Lletí M, Castro Hernández I, Giner L, Cobo J. Real-life experience with fidaxomicin in Clostridioides difficile infection: a multicentre cohort study on 244 episodes. Infection 2021;49:475-82. [PMID: 33417171 DOI: 10.1007/s15010-020-01567-5] [Reference Citation Analysis]